Free tool
Healthcare stocks
We cover 43 companies in the Healthcare sector. The median market value in the group is $1.20B. Across the group, the median move over the past trading day is +0.31%. 66% of the 41 with a 200-day average trade above it. Price change over the past year runs from −25.2% to +124.5% across the middle 80 percent of the group, with a median of −2.5%.
Other lists in this group
Table
43 of 2,203 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| JNJ.DE | Johnson & Johnson | $651.71B | Mega cap | +58.93% | Oct 13, 2026 |
| NOT.DE | Novartis AG | $300.14B | Mega cap | +28.89% | Oct 27, 2026 |
| TN8.DE | Thermo Fisher Scientific Inc. | $234.00B | Mega cap | +29.67% | Oct 21, 2026 |
| ABL.DE | Abbott Laboratories | $200.44B | Mega cap | −10.02% | Oct 14, 2026 |
| GETI-B.ST | Getinge AB (publ) | $7.01B | Mid cap | +20.89% | Oct 21, 2026 |
| SECT-B.ST | Sectra AB (publ) | $5.63B | Mid cap | −17.02% | Sep 4, 2026 |
| BBZA.DE | BB Biotech AG | $3.87B | Mid cap | +7.22% | Oct 23, 2026 |
| VIRP.PA | Virbac SA | $3.24B | Mid cap | −2.08% | Sep 17, 2026 |
| EMEIS.PA | emeis Société anonyme | $2.55B | Mid cap | +10.93% | Sep 23, 2026 |
| ALIF-B.ST | AddLife AB (publ) | $2.08B | Mid cap | −7.20% | Oct 21, 2026 |
| GNS.L | Genus plc | $2.08B | Mid cap | −12.94% | Sep 10, 2026 |
| NANO.PA | Nanobiotix S.A. | $2.05B | Mid cap | +358.21% | Sep 29, 2026 |
| VIMIAN.ST | Vimian Group AB (publ) | $1.99B | Small cap | +12.01% | Oct 22, 2026 |
| EMBLA.CO | Embla Medical hf. | $1.93B | Small cap | −6.94% | Oct 20, 2026 |
| BONEX.ST | Bonesupport Holding AB (publ) | $1.57B | Small cap | −28.26% | Oct 22, 2026 |
| DIA.WA | Diagnostyka S.A. | $1.54B | Small cap | −17.76% | Sep 10, 2026 |
| GDS.PA | Ramsay Générale de Santé SA | $1.42B | Small cap | +9.50% | Oct 16, 2026 |
| VITR.ST | Vitrolife AB (publ) | $1.35B | Small cap | −30.23% | Oct 22, 2026 |
| CHEMM.CO | ChemoMetec A/S | $1.33B | Small cap | −3.94% | Sep 10, 2026 |
| SPI.L | Spire Healthcare Group plc | $1.28B | Small cap | +7.25% | Sep 9, 2026 |
| BIOG-B.ST | BioGaia AB (publ) | $1.23B | Small cap | +13.96% | Oct 22, 2026 |
| CVSG.L | CVS Group plc | $1.20B | Small cap | +2.05% | Sep 24, 2026 |
| IVA.PA | Inventiva S.A. | $1.14B | Small cap | −14.63% | Sep 25, 2026 |
| TTALO.HE | Terveystalo Oyj | $1.14B | Small cap | −22.31% | Oct 21, 2026 |
| VETO.PA | Vetoquinol SA | $973.12M | Small cap | −6.37% | Sep 11, 2026 |
| XVIVO.ST | Xvivo Perfusion AB (publ) | $929.27M | Small cap | +59.31% | Oct 22, 2026 |
| MCAP.ST | MedCap AB (publ) | $864.73M | Small cap | −10.28% | Oct 23, 2026 |
| DYVOX.ST | Dynavox Group AB (publ) | $850.75M | Small cap | −39.29% | Oct 21, 2026 |
| OXB.L | Oxford Biomedica plc | $847.14M | Small cap | −9.81% | Sep 23, 2026 |
| GNFT.PA | Genfit S.A. | $830.56M | Small cap | +310.45% | Sep 29, 2026 |
| ARJO-B.ST | Arjo AB (publ) | $802.95M | Small cap | −15.25% | Oct 22, 2026 |
| EQS.PA | Equasens Société anonyme | $588.00M | Small cap | −25.98% | Sep 28, 2026 |
| MEDI.OL | Medistim ASA | $512.66M | Small cap | +4.43% | Oct 23, 2026 |
| REG1V.HE | Revenio Group Oyj | $494.52M | Small cap | −38.54% | Sep 8, 2026 |
| NIOX.L | NIOX Group Plc | $392.35M | Small cap | −9.49% | Sep 29, 2026 |
| CRNA.OL | Circio Holding ASA | $384.19M | Small cap | +1733.85% | Aug 31, 2026 |
| HUM.ST | Humana AB (publ) | $350.23M | Small cap | +81.84% | Oct 22, 2026 |
| TRMED.OL | Thor Medical ASA | $268.94M | Small cap | +135.13% | Aug 28, 2026 |
| XUP.DE | Genfit S.A. | $258.22M | Small cap | +166.82% | Sep 29, 2026 |
| IDD.DE | Innate Pharma S.A. | $243.27M | Small cap | −2.52% | Sep 17, 2026 |
| IPH.PA | Innate Pharma S.A. | $240.15M | Small cap | +1.19% | Sep 17, 2026 |
| ALCGM.PA | Cegedim SA | $166.24M | Small cap | −4.56% | Sep 24, 2026 |
| SEDANA.ST | Sedana Medical AB (publ) | $132.45M | Small cap | −22.05% | Oct 22, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.